These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Multicentre clinical trial of antirejection pulse therapy with deoxyspergualin in kidney transplant patients.
    Author: Amemiya H, Suzuki S, Ota K, Takahashi K, Sonoda T, Ishibashi M, Omoto R, Koyama F, Orita K, Takagi H.
    Journal: Int J Clin Pharmacol Res; 1991; 11(4):175-82. PubMed ID: 1813436.
    Abstract:
    The present randomized comparative clinical trial was carried out to confirm the efficacy of a newly developed immunosuppressive drug, 15-deoxyspergualin (DSG), and also to find its optimal dose for antirejection pulse therapy. The study included 66 patients with rejection which had occurred within 6 months after renal transplantation. They were treated with DSG at 3, 5 or 7 mg/kg/day for 5 days. The overall percentage of efficacy was 73% and the percentage of efficacy was the highest in the 3-mg/kg group (82%). The incidence of adverse reaction tended to be dose-dependent. From these results, the optimal dose of DSG was judged to be 3-5 mg/kg/day for antirejection pulse therapy, and at doses in this range the percent efficacy could be expected to be 80% or more.
    [Abstract] [Full Text] [Related] [New Search]